摘要
目的观察布地奈德联合利巴韦林雾化吸入治疗小儿毛细支气管炎的临床效果。方法选择我院2011年1月至2012年12月住院治疗的毛细支气管炎患儿84例,随机均分为观察组和对照组。观察组予布地奈德混悬液加利巴韦林雾化吸入治疗,对照组仅予利巴韦林雾化吸入治疗,一个疗程后观察比较两组患儿的治疗效果及不良反应。结果观察组咳嗽消失时间、憋喘消失时间、肺部啰音消失时间均少于对照组,差异有统计学意义(P<0.05);观察组总有效率明显高于对照组(92.86%vs.76.19%),差异有统计学意义(P<0.05)。两组均未观察到明显的药物不良反应。结论应用布地奈德混悬液联合利巴韦林雾化吸入治疗小儿毛细支气管炎,效果显著,不良反应少,值得临床推广应用。
Objective To observe the clinical efficacy of nebulized budesonide plus ribavirin in the treatment of children with bronchiolitis. Methods Eighty-four children with bronchiolitis from January 2011 to December 2012 were randomly divided into the observation group and control group, with 42 cases in each group. Patients in observation group were treated with nebulized budesonide plus ribavirin, while patients in control group were treated with nebulized ribavirin alone. The clinical efficiency and side effects were observed and compared between the two groups after a course of treatment. Results The disappearance times of coughing, wheezing, pulmonary rale in the observation group were shorter than those in the control group （P 〈0.05）, and the total efficiency of the observation group was significantly higher than that of the control group （92.86% vs. 76.19%）, with statistically significant difference （P 〈0.05）. No obvious adverse drug reaction was observed in both groups. Conclusions Nebulized budesonide plus ribavirin is effective in the treatment of children with bronchiolitis. It has fewer adverse reactions, which is worthy of clinical application.
出处
《临床医学工程》
2013年第8期997-998,共2页
Clinical Medicine & Engineering
